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Introduction {#sec1}
============

Organismal aging is accompanied by a gradual decline in regenerative capacities. This decline has been associated with reduced stem cell function, where the aging stem cell pool is unable to repopulate tissues upon cellular loss during physiological turnover or after tissue injury ([@bib4]). In the hematopoietic system, stem cell aging is evident in a weakening of the adaptive immune response and a general decline of hematopoietic stem cell fitness ([@bib4]).

The weakening immune response has been attributed to a shift from a balanced lymphoid/myeloid output toward a myeloid skew with age ([@bib28]). Although hematopoietic stem cells (HSCs) showing a skew in their myeloid/lymphoid output can also be found in young mice, the aggregate output is balanced. In contrast, with age, proportionally fewer lymphoid biased HSCs are found ([@bib11]).

In addition to the lineage skew, aging of the hematopoietic system also results in reduced performance in blood reconstitution and engraftment, regardless of lineage output ([@bib9]). In addition, accumulation of DNA damage and upregulation of p53 in aged HSC populations is well documented ([@bib8], [@bib29]). p53 is a key regulator of aging in hematopoiesis, with high levels of p53 leading to premature aging features, such as reduced engraftment ([@bib8]). However, while Grover and colleagues ([@bib11]) were able to shed light on the molecular signature responsible for lineage skewing with age, little is known about the molecular basis of the functional decline of HSCs with age. It is, for example, unknown how uniformly the functional impairment is distributed within the HSC compartment, and it is unclear what factors and pathways are directly relevant to the decline.

Using an index-sorting strategy and single-cell assays for highly purified long-term HSCs (LT-HSCs), we identified HSC aging as a heterogeneous process by characterizing an HSC subpopulation marked through p53 activation in old mice. Further transcriptional description of the subcluster shows myeloid bias as well as JAK/STAT- and MAPK (mitogen-activated protein kinase)-driven pro-proliferative gene signatures, reminiscent of the proliferation-driven cell-cycle arrest in cellular senescence ([@bib30]). Moreover, expansion of this old-specific subpopulation could be triggered by constitutively activating Jak2. We propose a model whereby prolonged proliferation in HSCs driven by the JAK/STAT pathway leads to a functionally impaired HSC subpopulation defined by p53 pathway upregulation with age.

Results {#sec2}
=======

The Long-Term HSC Compartment Harbors a Distinct Subpopulation with Age {#sec2.1}
-----------------------------------------------------------------------

To determine how the transcriptional heterogeneity in long-term HSCs is associated with age, we index-sorted single LT-HSCs using ESLAM markers ([Figure 1](#fig1){ref-type="fig"}A) from the bone marrow of mice aged 4 months old (n = 192) and 18 months old (n = 192). This approach resulted in a distinct HSC population evident through comparison with two published hematopoietic single-cell transcriptome datasets of young and old HSCs (lineage-negative Sca-1^+^, c-Kit^+^, CD150^+^, and CD48^−^) ([@bib11], [@bib18]), when projecting all datasets onto an HSC expression atlas ([@bib23]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We obtained 119/192 old and 99/192 young cells after quality control ([Figure S1](#mmc1){ref-type="supplementary-material"}B; [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) and used a k-means-based consensus clustering approach for single-cell transcriptomes (SC3) ([@bib17]).Figure 1LT-HSCs Display a Distinct Subpopulation with Age(A) Sorting strategy for HSCs.(B) SC3 clustering of young and old HSC transcriptomes. Replicates: purple and green bars. Age: orange (young) and turquoise (old) bars. Similarity between cells is indicated from blue to red (identical). Rep, replicate.(C) Heatmap of top ten marker genes of cluster 1. Expression is shown from blue (low) to red (high).(D) Silhouette plots for all clusters. The silhouette index (si) and the number of cells per cluster are given. xSi, average silhouette index.(E) Boxplots for ESLAM marker intensity for old-specific (blue) and other old (red) HSCs. Rel. Expr., relative expression.(F) SCDE plots for marker genes of cluster 1 in young (blue) and old (orange) HSCs. Expression levels of individual cells are indicated by individual lines.See also [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

One cluster was entirely made up of old HSCs from replicate mice (referred to as an "old-specific" cluster) ([Figure 1](#fig1){ref-type="fig"}B) being well defined as measured by silhouette index (\[Si\] 0.92; [Figure 1](#fig1){ref-type="fig"}D) and distinct. Marker genes driving cluster formation were calculated using SC3 (n = 62; [Figure 1](#fig1){ref-type="fig"}C; [Table S1](#mmc2){ref-type="supplementary-material"}). To investigate whether a similar cluster exists in young LT-HSCs, cells were clustered separately ([Figure S1](#mmc1){ref-type="supplementary-material"}C), with no similar cluster detectable ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Re-clustering old LT-HSCs separately identified the old-specific cluster with an identical subset of marker genes ([Figure S1](#mmc1){ref-type="supplementary-material"}C). To ensure that differences in cell type were not driving the clustering, we compared ESLAM markers from the index sort data with no difference in intensity of CD45 (p = 0.8925), CD48 (p = 0.4851), CD150 (p = 0.7208), or EPCR (p = 0.6472) expression ([Figure 1](#fig1){ref-type="fig"}E). To validate the marker genes, we used single-cell differential expression (SCDE) ([@bib15]) to identify differentially expressed genes between the old-specific subpopulation and the other HSCs. SCDE confirmed a subpopulation of old LT-HSCs expressing marker genes identified by SC3 ([Figure 1](#fig1){ref-type="fig"}F). In summary, we identified a transcriptionally distinct subpopulation of old LT-HSCs.

The Old-Specific Cluster Is Characterized by Anti- and Pro-proliferative Pathways {#sec2.2}
---------------------------------------------------------------------------------

To characterize the old-specific cluster, we characterized the marker genes underlying the clustering ([Figure 1](#fig1){ref-type="fig"}C; [Table S1](#mmc2){ref-type="supplementary-material"}). One of the top marker genes, the cell-cycle regulator Cdkn1a, is a well-known p53 target ([@bib3]), with p53 previously having been implicated in regulating HSC aging and quiescence ([@bib8]). To further test p53 regulation of the old-specific cluster, we used a list of senescence-specific p53 genes ([@bib16]). We identified a significant enrichment of marker genes as p53 related (6/68 marker genes, p = 1e−06; [Figure 2](#fig2){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}), many of which are negative regulators of proliferation. We were unable to identify enrichment of p53 apoptosis (p = 0.5; [@bib16]), autophagy (p = 0.06; [@bib14]), or checkpoint (p = 0.12; [@bib14]) targets in the marker genes ([Figure 2](#fig2){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}). No p53 targets were detected in the marker genes of the other five clusters in [Figure 1](#fig1){ref-type="fig"}C (see [Table S1](#mmc2){ref-type="supplementary-material"}).Figure 2Age-Specific Cluster Carries Signature of Pro-proliferative and Anti-proliferative Stimuli(A) Manual annotation of top 20 marker genes with Ras senescence (RIS), apoptosis ([@bib16]), and pStat3 and pStat5 datasets ([@bib20]). Red indicates p53, and green indicates pStat targets.(B) KEGG pathway analysis of marker genes for old-specific cluster. Selected pathways are shown as ratio of enrichment (green indicates pro-proliferative, and red indicates anti-proliferative).(C) GSEA for p53 RIS, apoptosis (Apo), and STAT3 and STAT5 targets. p values and enrichment scores are shown.(D) Schematic of TPO-regulated microarray experiment in HPC7. GSEA of TPO-specific targets and marker gene list.(E) IF quantification of old HSCs for p53Ser15 and/or gH2AX (n = 3; error bars indicate SEM).(F) Quantification of EdU (5-ethynyl-2′-deoxyuridine) incorporation, gH2AX, and p53 in old HSCs (n = 3; error bars indicates SEM).(G) GSEA for lineage markers.ChIP, chromatin immunoprecipitation, MA, microarray; TGF, transforming growth factor; n.s., not significant; nb, number of genes.

In the marker gene list, we noted multiple jun/fos transcription factors that are targets of JAK/STAT signaling in the hematopoietic system, where JAK/STAT stimulates proliferation and differentiation ([@bib27]). To test for enrichment of JAK/STAT targets, we compared the marker genes with chromatin immunoprecipitation sequencing (ChIP-seq) data from patient megakaryocytes, where the JAK/STAT pathway drives disease ([@bib20]). We identified a significant enrichment of STAT targets ([@bib20]) in our marker genes (green fields in [Figure 2](#fig2){ref-type="fig"}A: p = 0.0005 for pStat3 targets 6/68, and p = 0.0006 for pStat5 targets 4/68; [Table S1](#mmc2){ref-type="supplementary-material"}). No Stat3 or Stat5 targets were detected in the other five clusters in [Figure 1](#fig1){ref-type="fig"}C ([Table S1](#mmc2){ref-type="supplementary-material"}). In summary, analysis of the marker genes suggested a co-activation of cell-cycle repressing p53 and pro-proliferative JAK/STAT signaling in the old-specific cluster.

Several lines of evidence are consistent with the concept that pro-proliferative and anti- proliferative stimuli exist in the same old HSC subpopulation. First, unbiased KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis of the marker genes ([@bib12]) revealed an enrichment for "cell cycle" due to the presence of cell-cycle inhibitors, p53 targets ([Figure 2](#fig2){ref-type="fig"}B, red bars), and the MAPK pathway ([Figure 2](#fig2){ref-type="fig"}B, green bar), which is driven by JAK activation in hematological cells ([@bib33]).

Second, we compared gene target lists for p53, STAT3, and STAT5 to marker genes for the old-specific HSC cluster. Gene set enrichment analysis (GSEA) ([@bib31]) highlighted a significant enrichment of senescence-specific p53 (p53 enrichment score \[ES\] = 0.11, p = 0.009), STAT3 (ES = 0.137, p \< 0.001), and STAT5 (ES = 0.084, p = 0.039) targets in those marker genes ([Figure 2](#fig2){ref-type="fig"}C). No enrichment of apoptosis (no values returned; data not shown) or checkpoint-related p53 targets (p = 0.44; [Figure S2](#mmc1){ref-type="supplementary-material"}A) were detected. GSEA found no enrichment of p53 and STAT3/5 targets comparing pooled young and old HSCs (p = 0.422 for p53 apoptosis, p = 0.65 for p53 RIS, p = 0.44 for Stat5, and p = 0.357 for Stat3; [Figure S2](#mmc1){ref-type="supplementary-material"}B; data not shown).

Third, we generated a JAK/STAT signature mimicking HSC behavior by stimulating a stem-cell-like cell line (HPC7) with thrombopoietin (TPO) for microarray analysis ([Figure 2](#fig2){ref-type="fig"}D) ([@bib24]). Binding of TPO to its receptor activates JAK2 and its downstream targets STAT1, -3, and -5 ([@bib27]). GSEA highlighted a strong enrichment of TPO-regulated genes (top 100 genes, p \< 9.81e−10) in the old-specific cluster ([Figure 2](#fig2){ref-type="fig"}D).

Lastly, we confirmed the old-specific cluster by indirect immunofluorescence (IF) in HSCs from young and old mice (n = 3) for p53 phosphorylated at serine 15 (pp53Ser15) and FosB phosphorylated at serine 27 (pFosBSer27). Only old HSCs showed high levels of pp53Ser15 and pFosBSer27 ([Figure S2](#mmc1){ref-type="supplementary-material"}C). p53 response and senescence are associated with persistent levels of DNA damage. We stained old HSCs for p53 for gH2AX by IF and blind scored cells with more than five gH2AX foci. We found an enrichment for gH2AX over p53-positive cells ([Figure 2](#fig2){ref-type="fig"}E; [Figure S2](#mmc1){ref-type="supplementary-material"}D), providing a mechanism for p53 upregulation. We tested the gH2AX-positive old HSCs for changes to proliferation by EdU injection into mice and co-staining for gH2AXpSer139 protein using IF. EdU incorporation was absent from gH2AX-positive cells, suggesting reduced proliferation ([Figure 2](#fig2){ref-type="fig"}F).

The Old-Specific Cluster Is Enriched for Myeloid-Biased HSCs and Regulated by Transcription Factors Controlling Quiescence and Proliferation {#sec2.3}
--------------------------------------------------------------------------------------------------------------------------------------------

One feature of the aging HSC compartment, the myeloid basis, has been described on a single-cell basis ([@bib11]). To identify lineage biases in our old-specific cluster, we overlaid our marker gene list with gene sets for bi-potent granulocyte/macrophage progenitors (preGM), megakaryocyte/erythroid progenitors (preMeg), and common lymphoid progenitors (CLPs) using GSEA ([@bib26]). We identified an enrichment of preGM genes (ES = 0.2, p \< 0.01), with no enrichment in preMeg or CLP genes ([Figure 2](#fig2){ref-type="fig"}G), suggesting a myeloid bias in our old-specific HSC cluster. These results could explain the myeloid bias emerging with age where a subset of myeloid-primed HSCs reconstitute the blood system more frequently over time, followed by exhaust, leaving a large pool of myeloid-primed progenitors in the system.

We interrogated the marker genes specific to our old-specific HSCs with respect to regulation of HSC function and found 8/12 transcription factors regulating quiescence and proliferation ([Table S2](#mmc3){ref-type="supplementary-material"}, p = 6.779747e−24). Nuclear receptor subfamily 4 group A member 1 (Nr4a1) has been reported to be upregulated on myeloid-biased HSCs ([@bib19]), further supporting the myeloid bias. Perturbations of some marker genes have been reported and suggest an enrichment for quiescence regulators in the old-specific subcluster ([Table S3](#mmc4){ref-type="supplementary-material"}).

Constitutive Jak2 Activation Increases Contribution to the Age-Specific Subpopulation of LT-HSCs {#sec2.4}
------------------------------------------------------------------------------------------------

The upregulation of the p53 pathway in Jak2 context has previously been reported in erythroblasts from patients with myeloproliferative disease (MPN) ([@bib6]). In the majority of MPNs, Jak2 is constitutively active through a mutation leading to JAK2V617F ([@bib1]), where p53 is thought to maintain genome stability in the chronic phase of disease ([@bib6]). In this study, we did not observe activation of p53 in proliferating young HSCs ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C). One explanation for the lack of p53 activation in young HSCs is that p53 upregulation correlates with number of replications, similar to the role of p53 in replicative senescence ([@bib2]). To test the association between JAK/STAT-driven proliferation and p53 activation, we used single-cell approaches in homozygous JAK2V617F mice, where JAK2V617F provides a constant proliferative stimulus ([@bib22]). We first characterized proliferation kinetics of single young and old wild-type (WT) and JAK2V617F HSCs in vitro and found a significant increase in proliferation in young JAK2V617F HSCs after 72 hr in culture (p = 0.002, first division; p = 0.0001, second division; p = 0.0001, third division) ([Figures 3](#fig3){ref-type="fig"}A and 3B). Consistent with our transcriptomic data ([Figure 3](#fig3){ref-type="fig"}C), we failed to detect p53 activation in young JAK2V617F HSCs by IF for pp53Ser15 ([Figure 3](#fig3){ref-type="fig"}D), concluding that JAK2V617F increases proliferation without evoking a p53 response in young LT-HSCs. We tested whether JAK2V617F exerts an effect with age through a prolonged, lifelong increase in proliferation. We found two lines of evidence agreeing with prolonged, and not acutely enforced, proliferation evoking the old-associated p53 signature. First, we characterized the proliferation kinetics of single old JAK2V617F HSCs in vitro where old JAK2V617F HSCs show a loss of JAK2V617F-driven increased proliferation as measured by numbers of division at 72 hr in culture (p = 0.2117, first division; p = 0.0046, second division; p = 0.0039, third division). In agreement with published data in heterozygous JAK2V617F context ([@bib13]), old homozygous JAK2V617F HSCs show a significant decrease in average division when compared to old WT HSCs at 48 and 72 hr in culture (48 hr: p = 0.007, first division; p = 0.0001, second division; p = 0.106, third division; 72 hr: p = 0.0338, first division; p = 0.0004, second division; p = 0.2142, third division) ([Figures 3](#fig3){ref-type="fig"}A and 3B). In summary, the JAK2V617F-enhanced proliferative effect seen in young HSCs is lost in old HSCs.Figure 3Constitutively Active JAK2 Increases Cell Contribution to the Old-Specific Subpopulation(A) Kinetics of JAK2V617F and WT HSCs. Ratios of JAK2V617F and WT for indicated divisions in young (black) and old (gray) HSCs. Black line denotes WT levels (n = 3; error bars indicate SEM). Mut, mutated.(B) Kinetics data from young (upper row) and old (lower row) WT (blue) and homozygous (Hom) JAK2V671F (red) HSCs. Percentage of all cells upon division (n = 3; error bars indicate SEM). hrs, hours.(C) SC3 clustering of HSC transcriptomes from young (yg; upper orange bars) and old (upper turquoise bars) WT (lower orange bars) and JAK2V617F (lower turquoise bars) mice. Replicates are indicated in green and red. Similarity between cells is indicated from blue to red (identical).(D) SC3 clustering of old HSC transcriptomes from WT and JAK2V617F mice (replicate 1). Overlap with marker genes is given as a percentage. Cell number for old-specific HSCs is given as a percentage of all old HSCs.(E) Immunofluorescent images of old WT and JAK2V617F HSCs stained for pSer15p53 (green), pSer27FosB (red), and DAPI (blue). Bar plots quantify the percentage of double-positive HSCs from indicated mice (n = 3; error bars indicate SEM).(F) SC3 clustering of 1-year-old WT and JAK2V617F HSCs. Similarity between cells is indicated from blue to red (identical). Overlap with marker genes is shown in percentages.(G) Model for relation between proliferation and functional decline of HSCs. Compared are physiological (upper row) against enforced proliferation through JAK2V617F (lower row). Young HSCs in the JAK2 condition expand faster (number of cells) but exhaust more readily upregulating p53- and cyclin-dependent kinase inhibitors (CDKNs; shades of red). Arrow cycle indicates self-renewal.

Second, to establish causality for Jak2 driving the old-specific cluster formation, we tested the effect of the long-term increase in proliferation on individual cells in the aging HSC compartment using single-cell transcriptomics. We generated single-cell transcriptional profiles of young (n = 70) and old (n = 139) LT-HSCs homozygous for JAK2V617F ([@bib22]). Following clustering by SC3 ([@bib17]), we identified the same old-specific cluster as in the WT cells, evidenced by an identical set of marker genes ([Figure 3](#fig3){ref-type="fig"}E). A careful comparison of the number of cells in the old-specific cluster showed that it contained 26% and 33% of WT cells in replicates 1 and 2 respectively ([Figure 3](#fig3){ref-type="fig"}E; data not shown). In the JAK2V617V homozygous context, this contribution increased to 32% and 47% for replicates 1 and 2, respectively ([Figure 3](#fig3){ref-type="fig"}E; data not shown), a statistically non-significant increase (p = 0.146). To optimize the number of cells included in our analysis, we scored 1,463 cells from 3 old and 3 young WT and JAK2V617F mice ([Figure 3](#fig3){ref-type="fig"}D), by positive pp53Ser15 and pFosB IF. In old WT LT-HSCs, we found an increase of 36% in double-positive HSCs when compared to young WT HSCs, an increase consistent with our scRNA-seq data. The old-specific cluster expanded to 64% in JAK2V617F HSCs, consisting of significant increase compared to WT (p = 0.0001). To pinpoint the onset of the p53 signature in LT-HSCs, we generated single-cell transcriptional profiles of 12-month-old JAK2V617F mice (n = 2; 130 cells) and WT mice (n = 2; 144 cells) ([Figure 3](#fig3){ref-type="fig"}F). No overlap with the marker genes for the p53 cluster was found, suggesting that the onset of the p53 signature within LT-HSCs might be late in the mouse lifespan and a state switch-like, stochastic event. Taken together, our data suggest that pro-proliferating constitutive Jak2 activation expands the old-specific cluster, evoking a p53 response ([Figure 3](#fig3){ref-type="fig"}G). We hypothesize that enforced proliferation in young HSCs leads to stem cell exhaust and p53 activation with age.

Discussion {#sec3}
==========

The regenerative capacity of a tissue declines with age. Whether this reduction of stemness is equally distributed between stem cells or affects only a subset of cells is not well understood. In this study, only a distinct subpopulation of HSCs carried a signature indicative of functional decline as characterized by p53 signaling, pointing toward functionally heterogeneous stem cell aging. Whether this heterogeneous decline in function serves as a strategy to ensure stem cell function over an entire lifespan is unclear.

A role for p53 in hematopoietic aging has been established. In HSCs, increased p53 activity leads to reduced functionality and proliferation with age, whereas decreased p53 levels increase HSC proliferative capacity with age ([@bib8]), suggesting a direct link between p53 dosage and regenerative capacity in HSCs. Despite the wealth of phenotypical characterization of p53 dosage on the HSC compartment as a whole, our single-cell approach reveals how p53 activation is distributed within the HSC compartment and provides the missing deconvoluted transcriptional signatures of p53-activated and unactivated aged HSCs. Observations from studies in progeroid and hyperactivated p53 mouse models suggest a more generalized role for p53, possibly extending the relevance of our findings to non-hematopoietic tissues ([@bib34], [@bib32]). We found that p53-activated HSCs co-expressed cell-cycle inhibitory and proliferative transcripts from MAPK and JAK/STAT signaling. This co-activation of pro- and anti-proliferative pathways has been described in senescent cells induced by hyperactivation of MAPK signaling ([@bib30]). A role for JAK2 signaling has previously been implicated in the senescence induction of hematopoietic-lineage-negative Sca^+^c-Kit^+^ cells ([@bib21]) with accumulation of γH2Ax foci, reduced rates of proliferation, and inhibition of apoptosis. These phenomena were only observed 26 weeks after JAK2V617F induction, suggesting a cumulative rather than an immediate effect of JAK2V617F on proliferation ([@bib21]). A link between enforced proliferation and stem cell exhaustion has been shown where loss of CDKN1A drives HSCs into hyperproliferation and subsequent exhaust ([@bib7]). A recent study showed number of cell divisions as a limiting factor in HSC regenerative capacity ([@bib5]). Based on the co-activation of anti-proliferative pathways of p53 in individual HSCs, the opposing effects of JAK2V617F on HSC proliferation in young and old mice and the increase of p53-activated cells under prolonged, but not acute, JAK2V617F activation, we provide support for a link between cumulative proliferation and stem cell exhaustion with age.

We identified a myeloid bias in the old-specific HSC population that could not be detected in the other old HSCs ([Figure 2](#fig2){ref-type="fig"}F). Myeloid bias is well documented in the literature ([@bib28]), but molecular mechanisms are, thus far, elusive. We speculate that myeloid-biased HSCs proliferate more over the lifetime of a mouse, leading to HSC decline at the same time as providing a pool of myeloid-biased progenitors reconstituting the HSC compartment. This heterogeneity in HSC aging might be mediated by the bone marrow niche, where it has been shown that aged HSCs home further away from the endosteum compared to young HSCs, leading to decreased regenerative capacity ([@bib10]). However, this hypothesis awaits further investigation.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

Mice were generated as described previously ([@bib22]). All mice were kept in specific pathogen-free conditions and all procedures were performed according to rules of the Animal Welfare and Ethical Review Body (AWERB) and the UK Home Office regulations.

Cell Isolation and Flow Cytometry {#sec4.2}
---------------------------------

Single cells were obtained from bone marrow suspensions as described previously ([@bib13]). ESLAM cells were isolated using CD45-FITC (clone 30-F11), EPCR-PE (clone RMEPCR1560), CD150-Pacific Blue (clone TC15), and CD48-APC (clone HM48-1).

Single-Cell cDNA and Library Preparation {#sec4.3}
----------------------------------------

cDNA from single cells was obtained as described ([@bib25]). Illumina Nextera reagents were used for library construction and sequenced on the HiSeq 2500 Sequencing System (125-bp paired-end \[PE\] reads).

Data Analysis {#sec4.4}
-------------

Data analysis was performed using SC3 and SCDE tools ([@bib17], [@bib15]). For details, see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

IF {#sec4.5}
--

ESLAM cells were processed as described previously ([@bib21]), using anti-p-Serine15 p53 (clone 16G8), anti-p-Serine139 gH2AX (JBW39), and anti-p-Serine27 FosB (ab 62433) antibodies. Cells were blinded and scored on an AxioImager Z2 (Zeiss). A two-sided Fisher's exact test was used to calculate p values.

Single ESLAM Cultures {#sec4.6}
---------------------

Single ESLAM cells were cultured, blinded, and counted as described previously ([@bib13]). A two-sided Fisher's exact test was used to calculate the p values.

HPC7 Cell Culture and Microarray {#sec4.7}
--------------------------------

HPC7 cells were grown as described previously ([@bib24]). For microarray, cells were serum starved and stimulated with TPO for 30 min. Total RNA was extracted using the RNeasy Mini Kit (QIAGEN). Cambridge Genomic Services processed all samples using Illumina WG-6 BeadArrays. For data analysis, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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